Thrombosis, Lp(a) & residual risk

What actually decides this outcome, in order of size

Residual risk is what remains after the cholesterol number has been treated, and two things dominate it: a genetically set lipoprotein and the clotting response to a ruptured plaque. Ranked by how much of the outcome each factor owns:

1. Lipoprotein(a), which is set by genotype and is essentially immovable by diet, exercise or weight. The consensus position on its role in atherosclerotic disease and aortic stenosis is the reference document Kronenberg 2022, and the genetics and pathophysiology have been reviewed separately Volgman 2024. It is the single most informative test on this page and one of the least ordered, and the reason to measure it once is that the result never changes.
2. WHICH ASSAY REPORTED YOUR NUMBER, WHICH DECIDES WHAT THE NUMBER MEANS. Lipoprotein(a) particles vary in isoform size, and mass-based assays are affected by that variation; an isoform-independent monoclonal antibody-based assay was developed and validated for exactly this reason Marcovina 2022, five immunoassays have been compared on one platform Wyness 2021, and how and when to measure it has been set out in a practical review Cegla 2021. A result in mg/dL and a result in nmol/L are not interchangeable, and relating concentrations to event risk after acute coronary syndrome has been examined directly Szarek 2023. A method exists for quantifying the cholesterol carried on the particle rather than the particle mass Yeang 2021.
3. THE DIRECTION FAILURE, WHICH IS THAT LOWERING THE NUMBER HAS NOT BY ITSELF DELIVERED. The traditional lipid drugs that lower lipoprotein(a) have been assessed systematically for that effect Sinha 2024. Niacin is the worked example on this page's own item list: it lowers the number, and the outcome trials of the era did not reward it. That is the sign problem in its clearest form — a surrogate moved, an endpoint did not, and the product is still sold on the surrogate.
4. What actually happens at a plaque, which is a clotting event rather than a lipid one. Neutrophil activation and circulating neutrophil extracellular traps have been linked to venous thromboembolism Zapponi 2022, which is a reminder that thrombosis is a cellular and inflammatory process and not simply a viscosity problem — the model most of the enzyme products on this page are sold against.
5. Triglyceride-rich particles, where one prescription product has an outcome trial and a controversy. Icosapent ethyl reduced cardiovascular events in a randomized trial Bhatt 2019, with a coronary bypass subgroup reported separately Verma 2021 and the scientific and legal argument about the comparator oil documented Curfman 2021. Read all three; the third is why the effect size is still argued about.
6. Whether a raised D-dimer means anything in your context, which is mostly a pretest-probability question. The pitfalls of D-dimer testing have been reviewed Wauthier 2022, and ordering one without a clinical question generates alarm more reliably than information.

The order to run these in, and what has to be true first

Measure the thing that never changes once, treat the thing that responds, and be skeptical of anything sold for a number rather than for an event.

1. Lipoprotein(a) — Lp(a) once, in your life, and record the units. The practical guidance on when and how to measure it exists Cegla 2021, the assay differences are real Wyness 2021 Marcovina 2022, and the consensus statement is what to hand a clinician if it comes back high Kronenberg 2022. If it is high, first-degree relatives should be tested too Volgman 2024.
2. ApoB (Apolipoprotein B) with a Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) at the same draw. Particle number is the treatable driver and it is the one lipoprotein(a) sits on top of; the page for it is ApoB & LDL particle reduction.
3. Icosapent Ethyl is the item here with a cardiovascular outcome trial Bhatt 2019 Verma 2021, and with a documented argument about it Curfman 2021. It is a prescription decision and it is not the same product as fish oil.
4. Omega-3 (Fish Oil) and Super EPA (Fish Oil) are the supplement versions and are a triglyceride intervention rather than an event one. Mixed EPA and DHA preparations have not reproduced the icosapent result, and the comparator controversy is the reason that comparison is worth making carefully Curfman 2021.
5. Niacin (Flush) is the honest cautionary item on this page. It lowers lipoprotein(a) and that effect has been catalogued alongside the other traditional agents Sinha 2024. Lowering the number is not the same as reducing events, and this molecule is the reason that sentence exists in cardiology.
6. Nattokinase, Lumbrokinase and Serrapeptase are fibrinolytic-enzyme claims taken orally. The proposition is that an enzyme survives digestion, is absorbed intact and acts systemically on fibrin. That is a large pharmacokinetic claim for an oral protein and it is not established; treating them as blood thinners is a bleeding risk with an anticoagulant and an unmeasured one alone.
7. Aged Garlic Extract, Curcumin, Vitamin K2 Complex, NAC, Methylfolate (5-MTHF) and SPMs (Pro-Resolving Mediators) are the supporting shelf and each belongs to a different argument. Vitamin K2 is about calcification rather than clotting, and it interacts with warfarin, which makes it the one on this list with an interaction that matters.
8. D-Dimer only with a clinical question attached Wauthier 2022. It is a rule-out test in an assessed patient, not a screening test in a well person, and a raised result without context produces investigation rather than answers.

What gets bought for this that cannot move it

The category that fails structurally is the oral fibrinolytic enzyme. Nattokinase, Lumbrokinase and Serrapeptase are proteins, taken by mouth, expected to survive gastric acid and pancreatic proteases, cross the intestinal wall intact and then act on fibrin in the circulation. Each step in that chain is a large claim and none is established for these products at consumer doses. Meanwhile the process they are sold against is cellular and inflammatory as much as mechanical Zapponi 2022. Taken alongside a prescribed anticoagulant they are an unmeasured bleeding risk; taken alone they are an unmeasured nothing.

The direction failure is the one this page is named for. Lipoprotein(a) is a causal risk factor Kronenberg 2022 Volgman 2024, and the traditional drugs that lower it have been reviewed for that effect Sinha 2024. It does not follow that lowering it with those drugs lowers risk, and the niacin experience is the reason that distinction is now standard in the field. On this page the number matters enormously as information and very little as a target — which is an uncomfortable thing to say on a page that sells products, and it is the true state of the evidence.

The measurement failure is quieter and affects everybody who tests. Two laboratories can report the same particle burden as different numbers because of isoform effects and units Marcovina 2022 Wyness 2021 Yeang 2021. A reader who tests twice on two platforms and sees a change has usually measured the assay rather than themselves, and the relationship between concentration and risk depends on which measurement was made Szarek 2023.

If the goal underneath is different, so is the page. If particle number is the target, ApoB & LDL particle reduction. If it is endothelial function, Endothelial function & nitric oxide. If it is the venous circulation rather than the arterial one, Venous & microcirculation. And a personal or family history of clots at a young age is a hematology referral rather than a supplement question — the inherited thrombophilias have specific tests.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions. Lipoprotein(a) — Lp(a) will not change on anything in the supplement half, which is why it is a once-in-a-lifetime test rather than a monitored one Kronenberg 2022; and ApoB (Apolipoprotein B) is the number that will move on treatment, which makes it the read-out that tells you whether the plan is working at all.

• Lipoprotein(a) — Lp(a) once, with the units and the assay recorded. One measurement in a lifetime is the standard position Cegla 2021; repeating it on a different platform measures the platform Wyness 2021 Marcovina 2022.
• ApoB (Apolipoprotein B) with a Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) at baseline and 12 weeks. Twelve weeks because lipid responses to a real intervention are established by then, and because apolipoprotein B counts particles rather than estimating them.
• hs-CRP (High-Sensitivity C-Reactive Protein) at baseline and 12 weeks. The inflammatory half of residual risk, cheap, and interpretable only when drawn away from infection.
• Fibrinogen Activity at baseline if the enzyme products are being taken seriously. It is the closest routinely available number to what those products claim to affect, and a flat fibrinogen after months of an oral enzyme is the cheapest available falsification of the whole category.
• D-Dimer only if there is a clinical question, and Factor V Leiden Mutation, DNA with Factor II Activity (Prothrombin) only with a personal or family history of venous clots. D-dimer has documented pitfalls as a stand-alone test Wauthier 2022, and the inherited thrombophilia panel is a targeted investigation rather than a screen.

What will fool you. A lipoprotein(a) reported in mg/dL compared against a threshold quoted in nmol/L will produce a wrong conclusion in either direction Cegla 2021. A falling number on niacin is a surrogate response and the outcome literature is why that is not reassuring Sinha 2024. A raised D-dimer after a long flight, an infection or surgery is common and rarely means what the reader fears Wauthier 2022. Fish oil marketed on the icosapent trial is a different molecule from the one that was tested Bhatt 2019 Curfman 2021. And the absence of symptoms means nothing here — this entire page is about risk that is silent until it is not.

Sources read for these sections

• Sinha M. Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review. Cureus 2024 · PMID 39435209
• Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. European Heart Journal 2022 · PMID 36036785
• Cegla J, et al. Lp(a): When and how to measure it. Annals of Clinical Biochemistry 2021 · PMID 33040574
• Marcovina SM, et al. Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). Journal of Lipid Research 2022 · PMID 35688187
• Wyness SP, et al. Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer. Practical Laboratory Medicine 2021 · PMID 33898688
• Yeang C, et al. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of Lipid Research 2021 · PMID 33636163
• Szarek M, et al. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation 2023 · PMID 37632469
• Volgman AS, et al. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk. Journal of the American Heart Association 2024 · PMID 38879448
• Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine 2019 · PMID 30415628
• Curfman G, et al. Icosapent ethyl: scientific and legal controversies. Open Heart 2021 · PMID 33888593
• Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation 2021 · PMID 34710343
• Zapponi KCS, et al. Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event. Journal of Thrombosis and Thrombolysis 2022 · PMID 34449018
• Wauthier L, et al. D-dimer Testing in Pulmonary Embolism with a Focus on Potential Pitfalls: A Narrative Review. Diagnostics 2022 · PMID 36428830